Texaphyrins: Tumor localizing redox active expanded porphyrins

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 222-232

  Arambula, Jonathan F ^a,b   Preihs, Christian ^a   Borthwick, Derric ^a   Magda, Darren ^c   Sessler, Jonathan L ^a,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Lumiphore Inc   (United States)

^d Yonsei University   (South Korea)

Author keywords

Alpha and beta core emitters; Anticancer activity; Mechanism of action; Platinum delivery; Reactive oxygen species; Texaphyrin; Zinc

Indexed keywords

CARBOPLATIN; CISPLATIN; PORPHYRIN DERIVATIVE; TEXAPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 79953794149     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795255894     Document Type: Review

References (123)

1. McCord, J. M.; Fridovich, I. The reduction of cytochrome c by milk xanthine oxidase. J. Biol. Chem., 1968, 243, 5753.
2. McCord, J. M.; Fridovich, I. Superoxide dismutase: the first twenty years (1968-1988). Free Rad. Biol. Med., 1988, 5, 363.
3. Mehta, M. P.; Shapiro, W. R.; Phan, S. C.; Gervais, R.; Carrie, C.; Chabot, P.; Patchell, R. A.; Glantz, M. J.; Recht, L.; Langer, C.; Sur, R. K.; Roa, W. H.; Mahe, M. A.; Fortin, A.; Nieder, C.; Meyers, C. A.; Smith, J. A.; Miller, R. A.; Renschler, M. F. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys., 2009, 73, 1069.
4. Patel, H.; Mick, R.; Finlay, J.; Zhu, T. C.; Rickter, E.; Cengel, K. A.; Malkowicz, S. B.; Hahn, S. M.; Busch, T. M. Motexafin lutetium-photodynamic therapy of prostate cancer: short-and longterm effects on prostate-specific antigen. Clin. Cancer Res., 2008, 14, 4869.
5. Sessler, J. L.; Hemmi, G.; Mody, T. D.; Murai, T.; Burrell, A.; Young, S. W. Texaphyrins: Synthesis and applications. Acc. Chem. Res., 1994, 27, 43.
6. Magda, D.; Miller, R. A. Motexafin gadolinium: A novel redox active drug for cancer therapy. Seminars in Cancer Biol., 2006, 16, 446.
7. Riley, D. P. Functional mimics of superoxide dismutase enzymes as therapeutic agents. Chem. Rev., 1999, 99, 2573.
8. Doctrow, S. R.; Adinolfi, C. A.; Baudry, M.; Huffman, K.; Malfroy, B.; Marcus, C. B.; Melov, S.; Pong, K.; Rong, Y.; Smart, J. L.; Tocco, G. Salen Manganese complexes, combined with superoxide dismutase/catalase mimetics, demonstrate potential for treating neurodegenerative and other age-associated diseases. Crit. Rev. Oxid. Stress Aging, 2003, 2, 1324.
9. Salvemini, D.; Muscoli, C.; Riley, D. P.; Cuzzocrea, S. Superoxide dismutase mimetics. Pulmonary Pharmacol. and Therap. 2002, 15, 439.
10. Groves, J. T. Peroxynitrite: Reactive, Invasive, and Enigmatic. Peroxynitrite: Reactive, Invasive, and Enigmatic. Curr. Op. Chem. Biol., 1999, 3, 226.
11. Lee, J.; Hunt, J. A.; Groves, J. T. Mechanisms of Iron Porphyrin Reactions with Peroxynitrite. J. Am. Chem. Soc., 1998, 120, 7493.
12. Lee, J.; Hunt, J. A.; Groves, J. T. Manganese porphyrins as redoxcoupled peroxynitrite reductases. J. Am. Chem. Soc., 1998, 120, 6053.
13. Shimanovich, R.; Groves, J. T. Mechanisms of peroxynitrite decomposition catalyzed by FeTMPS, a bioactive sulfonated iron porphyrin. Arch. Biochem. Biophys., 2001, 387, 307.
14. Shimanovich, R.; Hannah, S.; Lynch, V.; Gerasimchuk, N.; Mody, T. D.; Magda, D.; Sessler, J. L.; Groves, J. T. Mn(II)-Texaphyrin as a catalyst for the decomposition of peroxynitrite. J. Am. Chem. Soc. 2001, 123, 3613.
15. Crow, J. P. "Administration of Mn porphyrin and Mn Texaphyrin at symptom onset extends survival of ALS Mice," in ACS Symposium Series No. 903; Eds. Sessler, J. L.; Doctrow, S. R.; McMurry, T.; Lippard, S. J.; American Chemical Society: Washington, DC, 2005.
16. Wu, A. S.; Kiaei, M.; Aguirre, N.; Crow, J. P.; Calingasan, N. Y.; Browne, S. E.; Beal, M. F. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurochem., 2003, 85, 142.
17. Crow, J. P. Peroxynitrite scavenging by metalloporphyrins and thiolates. Free Rad. Biol. Med., 2000, 28, 1487.
18. Crow, J. P. Manganese and iron porphyrins catalyze peroxynitrite decomposition and simultaneously increase nitration and oxidant yield: Implications for their use as peroxynitrite scavengers in vivo. Arch. Biochem. Biophys., 1999, 371, 41.
19. Browne, S. E.; Roberts II, L. J.; Dennery, P. A.; Doctrow, S. R.; Beal, M. F.; Barlow, C.; Levine, R. L. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxiatelangiectasia mice. Free Rad. Biol. Med., 2004, 36, 938.
20. Doctrow, S. R.; Huffman, K.; Marcus, C. B.; Tocco, G.; Malfroy, E.; Adinolfi, C. A.; Kruk, H.; Baker, K.; Lazarowych, N.; Mascarenhas, J.; Malfroy, B. Salen-manganese complexes as catalytic scavengers of hyrogen peroxide and cytoprotective agents: Structure-activity relationships Studies. J. Med. Chem., 2002, 45, 4549.
21. Liu, R.; Liu, I. Y.; Bi, X.; Thompson, R. F.; Doctrow, S. R.; Malfroy, B.; Baudry, M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc. Natl. Acad. Sci., USA, 2003, 100, 8526.
22. Melov, S.; Ravenscroft, J.; Sarwatt, M.; Gill, M. S.; Walker, D. W.; Clayton, P. E.; Wallace, D. C.; Malfroy, B.; Doctrow, S. R.; Lithgow, G. J. Extension of life-span with superoxide dismutase/ catalase mimetics. Science, 2000, 289, 1567.
23. Melov, S.; Wolf, N.; Strozyk, D.; Doctrow, S. R.; Bush, A. I. Mice transgenic for alzheimer disease t-Amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Rad. Biol. Med., 2005, 38, 258.
24. Zhang, H. J.; Doctrow, S. R.; Xu, L.; Oberley, L. W.; Beecher, B.; Morrison, J.; Oberley, T. D.; Kregel, K. C. Redox Modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress. FASEB J., 2004, 18, 1547.
25. Doctrow, S. R.; Baudry, M.; Huffman, K.; Malfroy, B.; Melov, S. "Salen manganese complexes. multifunctional catalytic antioxidants protective models for neurodegenerative diseases of aging," in ACS Symposium Series No. 903; Eds. Sessler, J. L., Doctrow, S. R., McMurry, T., Lippard, S. J.; American Chemical Society: Washington, DC, 2005.
26. Cabelli, D.; Riley, D.; Rodriguez, J. A.; Valentine, J. S.; Zhu, H. "Models of superoxide dismutases," in Biomimetic Oxidations Catalyzed by Transition Metal Complexes; Ed. Meunier, B.; Imperial College Press: London, UK, 2000.
27. Szabo, C.; Day, B. J.; Salzman, A. L. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett., 1996, 381, 82.
28. Day, B. J.; Batinic-Haberle, I.; Crapo, J. D. Metalloporphyrins are potent inhibitors of lipid peroxidation. Free Rad. Biol. Med., 1999, 26, 730.
29. Kasugi, N.; Murase, T.; Ohse, T.; Nagaoka, S.; Kawakami, H.; Kubota, S. Selective cell death by water-soluble Fe-porphyrins with superoxide dismutase (SOD) activity. J. Inorg. Biochem., 2002, 91, 349.
30. Casolaro, M.; Chelli, M.; Ginanneschi, M.; Laschi, F.; Messori, L.; Muniz-Miranda, M.; Papini, A. M.; Kowalik-Jankowska, T.; Kozlowski, H. Spectroscopic and potentiometric study of the SOD mimic system copper(II)/Acetyl-L-Histidylglycyl-L-Histidylglycine. J. Inorg. Biochem., 2002, 89, 181.
31. Gonzalez-Alvarez; Alzuet, G.; Borras, J.; Agudo, L. C.; Montejo-Bernardo, J. M.; Garcia-Granda, S. Development of novel copper(II) complexes of Benzothiazole-N-sulfonamides as protective agents against superoxide anion. J. Biol. Inorg. Chem., 2003, 8, 112.
32. Bailey, M. A.; Ingram, M. J.; Naughton, D. P. A novel anti-oxidant and anti-cancer strategy: A peptoid anti-inflammatory drug conjugate with SOD mimic activity. Biochem. Biophys. Res. Comm., 2004, 317, 1155.
33. Haj-Yehia, A.; Nassar, T.; Lotan, C.; Munzel, T.; Benet, L.; Anggard, E. E. Development of 3-Nitratomethyl-PROXYL (NMP): A novel, bifunctional superoxide dismutase-mimic-nitric oxidedonor. Drug Development Res., 2000, 50, 528.
34. Goldstein, S.; Merenyi, G.; Russo, A.; Samun, A. The Role of Oxoammonium Cation in the SOD-Mimic Activity of Cyclic Nitroxides. J. Am. Chem. Soc., 2003, 125, 789.
35. Hoffman, A.; Goldstein, S.; Samuni, A.; Borman, J. B.; Schwalb, H. Effect of nitric oxide and nitroxide SOD-mimic on the recovery of isolated rat heart following ischemia and repersfusion. Biochem. Pharmacol., 2003, 66, 1279.
36. Muscoli, C.; Cuzzocrea, S.; Riley, D. P.; Zweier, J. L.; Thiemermann, C.; Wang, Z.-Q.; Salvemini, D. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Brit. J. Pharmacol., 2003, 140, 445.
37. Batinic-Haberle, I.; Reboucas, J. S.; Spasojevic, I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Sig., 2010, 13, 877.
38. Batinic-Haberle, I.; Spasojevic, I.; Fridovich, I. Tetrahydrobiopterin rapidly reduces the SOD Mimic Mn(III) ortho-Tetrakis(NEthylpyridinium-2-yl)Porphyrin. Free Rad. Biol. Med., 2004, 37, 367.
39. Reboucas, J. S.; Kos, I.; Vujaskovic, Z.; Batinic-Haberle, I. Determination of residual manganese in Mn porphyrin-based superoxide dismutase (SOD) and peroxynitrite reductase mimics. J. Pharm. Biomed. Anal., 2009, 50, 1088.
40. - dismutation. Mn(III) ortho-methoxyethylpyridyland di-ortho-methoxyethyl-imidazolylporphyrins. Dalton Trans., 2004, 1696.
41. Okado-Matsumoto, A.; Batinic-Haberle, I.; Fridovich, I. Complementation of SOD-deficient escherichia coli by manganese porphyrin mimics of superoxide dismutase activity. Free Rad. Biol. Med., 2004, 37, 401.
42. Spasojevic, I.; Batinic-Haberle, I.; Reboucas, J. S.; Idemori, Y. M.; Fridovich, I. Electrostatic contribution in the catalysis of O2*-dismutation by superoxide dismutase mimics. MnIIITE-2-PyP5+ versus MnIIIBr8T-2-PyP+. J. Biol. Chem., 2003, 278, 6831.
43. Vujaskovic, Z.; Batinic-Haberle, I.; Rabbani, Z. N.; Feng, Q.-F.; Kang, S. K.; Spasojevic, I.; Samulski, T. V.; Fridovich, I.; Dewhirst, M. W.; Anscher, M. S. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Rad. Biol. Med., 2002, 33, 857.
44. Spasojevic, I.; Batinic-Haberle, I.; Stevens, R. D.; Hambright, P.; Thorpe, A. N.; Grodkowski, J.; Neta, P.; Fridovich, I. Manganese(III) biliverdin IX dimethyl ester: a powerful catalytic scavenger of superoxide employing the Mn(III)/Mn(IV) redox couple. Inorg. Chem., 2001, 40, 726.
45. Day, B. J.; Fridovich, I.; Crapo, J. D. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch. Biochem. Biophys., 1997, 347, 256.
46. Liochev, S. I.; Fridovich, I. Carbon dioxide mediates Mn(II)-catalyzed decomposition of hydrogen peroxide and peroxidation reactions. Proc. Natl. Acad. Sci. U.S.A, 2004, 101, 12485.
47. Ferrer-Sueta, G.; Vitturi, D.; Batinic-Haberle, I.; Fridovich, I.; Goldstein, S.; Czapski, G.; Radi, R. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J. Biol. Chem., 2003, 278, 27432.
48. Galm, U.; Hager, M. H.; Van Lanen, S. G.; Ju, J.; Thorson, J. S.; Shen, B. Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem. Rev., 2005, 105, 739.
49. Tomasz, M. Mitomycin C: small, fast and deadly (but very selective). Chem. Biol., 1995, 2, 575.
50. de Groot, F. M. H.; Damen, E. W. P.; Scheeren, H. W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumorassociated enzymes, and receptors. Curr. Med. Chem., 2001, 8, 1093.
51. Chen, J.; Stubbe, J. A. Bleomycins: new methods will allow reinvestigation of old issues. Curr. Opinion Chem. Biol., 2004, 8, 175.
52. Tuttle, S.; Horan, A. M.; Koch, C. J.; Held, K.; Manevich, Y.; Biaglow, J. Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-L-cysteine or L-buthionine-S, R-sulfoximine. Int. J. Radiat. Oncol. Biol. Phys., 1998, 42, 833.
53. Obrador, E.; Navarro, J.; Mompo, J.; Asensi, M.; Pellicer, J. A.; Estrela, J. M. Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: role of glutathione. BioFactors, 1998, 8, 23.
54. Magda, D.; Lepp, C.; Gerasimchuk, N.; Lee, I.; Sessler, J. L.; Lin, A.; Biaglow, J.; Miller, R. A. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Biol. Oncol. Phys., 2001, 51, 1025.
55. Wei, S. J.; Botero, A.; Hirota, K.; Bradbury, C. M.; Markovina, S.; Laszlo, A.; Spitz, D. R.; Goswami, P. C.; Yodoi, J.; Gius, D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer. Res., 2000, 60, 6688.
56. Kirkpatrick, D. L.; Ehrmantraut, G.; Stettner, S.; Kunkel, M.; Powis, G. Redox active disulfides: the thioredoxin system as a drug target. Oncol. Res., 1997, 9, 351.
57. McNaughton, M.; Engman, L.; Birmingham, A.; Powis, G.; Cotgreave, I. A. Cyclodextrin-derived Diorganyl Tellurides as Glutathione Peroxidase Mimics and Inhibitors of Thioredoxin Reductase and Cancer Cell Growth. J. Med. Chem., 2004, 47, 233.
58. Buettner, G. R. The Pecking Order of Free Radicals and Antioxidants: Lipid Peroxidation. Arch. Biochem. Biophys., 1993, 300, 535.
59. Byrne, A.T.; Magda, D.; Nguyen, H.; Miles, D.; Boswell, G.; Miller, R. A. Selective tumor localization with motexafin gadolinium (MGd) and motexafin lutetium (MLu) occurs by active transport. AACR; American Association for Cancer Research (AACR); Toronto, Ontario, Canada, 2003 p. 393.
60. Woodburn, K. W.; Fan, Q.; Miles, D. R.; Kessel, D.;, Luo, Y.; Young, S. W. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem. Photobiol. Photochem. Photobiol., 1997, 65, 410.
61. Miles, D. R.; Mesfin, M.; Mody, T. D.; Stiles, M.; Lee, J.; Fiene, J, Denis, B.; Boswell, G. W. Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues. Anal. Bioanal. Chem., 2006, 385, 345.
62. Donnelly, E. T.; Liu, Y.; Fatunmbi, Y. O.; Lee, I.; Magda, D.; Rockwell, S. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 1570.
63. Bohmer, R. M.; Morstyn, G. Uptake of hematoporphyrin derivative by normal and malignant cells: effect of serum, pH, temperature, and cell size. Cancer Res., 1985, 45, 5328.
64. Rockwell, S.; Donnelly, E. T.; Liu, Y.; Tang, L.-Q. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 2002, 54, 536.
65. Bernhard, E. J.; Mitchell, J. B.; Deen, D.; Cardell, M.; Rosenthal, D. I.; Brown, J. M. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Canc. Res., 2000, 60, 86.
66. Lin, T. S.; Naumovski, L.; Lecane, P.S.; Lucas, M. S.; Moran, M. E.; Cheney, C.; Lucas, D. M.; Phan, S. C.; Miller, R.A.; Byrd, J. C. Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk. Lymphoma, 2009, 50, 1977.
67. Guldi, D. M.; Mody, T. D.; Gerasimchuk, N. N.; Magda, D.; Sessler, J. L. Influence of Large Metal Cations on the Photophysical Properties of Texaphyrin, a Rigid Aromatic Chromophore. J. Am. Chem. Soc., 2000, 122, 8289.
68. Magda, D. J.; Sessler, J. L.; Gerasimchuk, N.; Miller, R. A. "Gadolium(III) Texaphyrin (Xcytrin®): A New Class of Redox Active Drug Leads," in Medicinal Inorganic Chemistry--ACS Symposium Series No. 903; Eds. Sessler, J.L.; Doctrow, S.R., McMurry, T.; Lippard, S.J.; Oxford University Press; 2005.
69. Magda, D.; Lepp, C.; Gerasimchuk, N.; Lecane, P.; Miller, R. A.; Biaglow, J. E.; Sessler, J. L. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem. Commun., 2002, 2730.
70. Hannah, S.; Lynch, V.; Guldi, D. M.; Gerasimchuk, N.; MacDonald, C. L. B.; Magda, D.; Sessler, J. L. Late first-row transition-metal complexes of texaphyrin. J. Am. Chem. Soc., 2002, 124, 8416.
71. Fu, L.; Carey, D.; Mody, T. Preparation of Metallotexaphyrins. U.S. Patent WO2004050716, 2004.
72. Biaglow, J. E.; Miller, R. A.; Magda, D.; Lee, I.; Tuttle, S. Prog. Abst. Radiat. Res. Soc., 2002, 107.
73. Wei, W.-h; Wang, Z.; Magda, D.; Sessler, J. L. New polyethyleneglycol-functionalized texaphyrins: synthesis and in vitro biological studies. Dalton Trans., 2006, 1934.
74. Hashemy, S. I.; Ungerstedt, J. S.; Zahedi Avval, F.; Holmgren, A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006, 281, 10691.
75. Arner, E. S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem., 2000, 267, 6102.
76. Smart, D. K.; Ortiz, K. L.; Mattson, D.; Bradbury, C. M.; Bisht, K. S.; Sieck, L. K.; Brechbiel, M. W.; Gius, D. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res., 2004, 64, 6716.
77. Kagi, J. H. R.; Schaffer, A. Bichemistry of metallothionein. Biochemistry, 1988, 27, 8509.
78. Vallee, B. L. Introduction to metallothionein. Methods Enzymology, 1991, 205, 3-7.
79. Cherian, M. G.; Jayasurya, A.; Bay, B. H. Metallothioneins in human tumors and potential roles in carcionogenesis. Mutat. Res., 2003, 533, 201.
80. Giedroc, D. P.; Chen, X.; Apuy, J. L. Metal response element (MRE)-binding transcription factor-2 (MTF-1): structure, function, and regulation. Antioxid. Redox Signal, 2001, 3, 577.
81. Hasumi, M.; Suzuki, K.; Matsui, H.; Koike, H.; Ito, K.; Yamanaka, H. Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett., 2003, 200, 187.
82. Cousins, R. J.; Blanchard, R. K.; Popp, M. P.; Liu, L.; Cao, J.; Moore, J. B.; Green, C. L. A global view of the selectivity of zinc deprivation and excess on genes expressed in human THP-1 mononuclear cells. Proc. Natl. Acad. Sci., USA, 2003, 100, 6952.
83. Langmade, S. J.; Ravindra, R.; Daniels, P. J.; Andrews, G. K. The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J. Biol. Chem., 2000, 275, 34803.
84. Lichtlen, P.; Schaffner, W. Putting its fingers on stressful situations: the heavy metal-regulatory transcription factor MTF-1. Bioessays, 2001, 23, 1010.
85. Lichtlen, P.; Wang, Y.; Belser, T.; Georgiev, O.; Certa, U.; Sack, R.; Schaffner, W. Target gene search for the metal-responsive transcription factor MTF-1. Nucleic Acids Res., 2001, 29, 1514.
86. Andrews, G. K. Cellular zinc sensors: MTF-1 regulation of gene expression. Biometals, 2001, 14, 223.
87. Magda, D.; Lecane, P.; Miller, R. A.; Lepp, C.; Miles, D.; Mesfin, M.; Biaglow, J. E.; Ho, V. V.; Chawannakul, D.; Nagpal, S.; Karaman, M. W.; Hacia, J. G. Motexafin Gadolinium and Zinc Induce Oxidative Stress Responses and Apoptosis in B-Cell Lymphoma Lines. Canc. Res., 2005, 65, 3837.
88. Biaglow, J. E.; Donahue, J.; Tuttle, S.; Held, K.; Chrestensen, C.; Mieyal, J. A method for measuring disulfide reduction by cultured ammalian cells: relative contributions of gluthione-dependent and glutathione-independent mechanisms. Anal. Biochem., 2000, 281, 77.
89. Gee, K. R.; Zhou, Z. L.; Ton-That, D.; Sensi, S. L.; Weiss, J. H. Measuring zinc in living cells. A new generation of sensitive and selective fluorescent probes. Cell Calcium, 2002, 31, 245.
90. Lecane, P.; Karaman, M. W.; Sirisawad, M.; Naumovski, L.; Miller, R. A.; Hacia, J. G.; Magda, D. Motexafin Gadolinium and Zinc Induce Oxidative Stress Responses and Apoptosis in B-Cell Lymphoma Lines. Cancer Res., 2005, 65, 11676.
91. Hirsila, M.; Koivunen, P.; Xu, L.; Seeley, T.; Kivirikko, K. I.; Myllyharju, J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEBJ., 2005, 19, 1308.
92. Schofield, C. J.; Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol., 2004, 5, 343.
93. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3, 721.
94. Choi, J. H.; Kim, T. N.; Kim, S.; Baek, S.; Kim, J.; Lee, S.; Kim, JR. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res., 2002, 22, 3331.
95. Kirkpatrick, D. L.; Kuperus, M.; Dowdeswell, M.; Potier, N.; Donald, L.; Kunkel, M.; Berggren, M; Angulo, M.; Powis, G. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol., 1998, 55, 987-94.
96. Mehta, M.P.; Rodrigus, P.; Terhaard, C.H.; Rao, A.; Suh, J.; Roa, W.; Souhami, L.; Bezjak, A.; Leibenhaut, M.; Komaki, R.; Schultz, C.; Timmerman, R.; Curran, W.; Smith, J.; Phan, S.; Miller, R.A.; Renschler, M. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol., 2003, 21, 2529.
97. Gibson, W. B.; Jeffcoat, A. R.; Turan, T. S.; Wendt, R. H.; Hughes, P. F.; Twine, M. E. Zinc pyridinethione: serum metabolites of zinc pyridinethione in rabbits, rats, monkeys, and dogs after oral dosing. Toxicol. Appl. Pharmacol., 1982, 62, 237.
98. Jeffcoat, A. R.; Gibson, W. B.; Rodriguez, P. A.; Turan, T. S.; Hughes, P. F.; Twine, M. E. Zinc pyridinethione: urinary metabolites of zinc pyridinethione in rabbits, rats, monkeys, and dogs after oral dosing. Toxicol. Appl. Pharmacol., 1980, 56, 141.
99. Jasim, S.; Tjalve, H. Effect of zinc pyridinethione on the tissue disposition of nickel and cadmium in mice. Acta. Pharmacol. Toxicol. (Copenh), 1986, 59, 204.
100. Jasim, S.; Tjalve, H. Effect of sodium pyridinethione on the uptake and distribution of nickel, cadmium and zinc in pregnant and nonpregnant mice. Toxicology, 1986, 38, 327.
101. Doose, C. A.; Ranke, J.; Stock, F.; Bottin-Weber, U.; Jastorff, B. Structure-activity relationships of pyrithiones-IPC-81 toxicity tests with the antifouling biocide zinc pyrithione and structural analogs. Green Chem., 2004, 6, 259.
102. Magda, D.; Lecane, P.; Wang, Z.; Hu, W.; Thiemann, P.; Ma, X.; Dranchak, P.; Wang, X.; Lynch, V.; Wei, W.; Csokai, V.; Hacia, J.; Sessler, J. Synthesis and Anticancer Properties of Water-Soluble Zinc Ionophores. Cancer Res., 2008, 68, 13, 5318.
103. Bosl, G. J., Bajorin, D. F. & Sheinfeld, J. Cancer of the Testis (eds DeVita, V. T. J., Hellman, S. & Rosenberg, S. A.) (Lippincott Williams & Wilkins, Philadelphia, 2001).
104. Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev., 1999, 99, 2467.
105. Kelland, L. R.; Sharp, S. Y.; O'Neill, C. F.; Raynaud, F. I.; Beale, P. J.; Judson, I. R. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem., 1999, 77, 111.
106. Fuertes, M. A.; Alonso, C.; Pérez, J.-M. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003, 103, 645.
107. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265.
108. Aronov, O.; Horowitz, A. T.; Gabizon, A.; Fuertes, M. A.; Perez, J. M.; Gibson, D. Nuclear Localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjugate Chem., 2004, 15, 814.
109. Aronov, O.; Horowitz, A. T.; Gabizon, A.; Gibson D. Folate-Targeted PEG as a Potential Carrier for Carboplatin Analogs. Synthesis and in Vitro Studies. Bioconjugate Chem., 2003, 14, 563.
110. Lottner, C.; Knuechel, R.; Bernhardt, G.; Brunner, H. Distribution and cellular localization of a water-soluble hematoporphyrinplatinum(II) complex in human bladder cancer cells. Cancer Lett., 2004, 215, 167.
111. Barnes, K. R.; Kutikov, A.; Lippard, S. J. Synthesis, characterization and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol., 2004, 11, 557.
112. Galanski, M. and Keppler, B. K. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents in Med. Chem., 2007, 7, 55.
113. van Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev., 2005, 249, 2845.
114. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature. Bioconjugate Chem., 2008, 19, 39.
115. Dhar, S.; Daniel, W. L.; Giljohann, D. A.; Mirkin, C. A.; Lippard, S. J. Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads. J. Am. Chem. Soc., 2009, 131, 14652.
116. Arambula, J. F.; Sessler, J. L.; Fountain, M.; Wei, W.-h.; Magda, D.; Siddik, Z. H. Gadolinium texaphyrin (Gd-Tex)-malonatoplatinum conjugates: Synthesis and comparison with carboplatin in normal and Pt-resistent cells. Dalton Trans., 2009, 48, 10834.
117. Arambula, J. F.; Sessler, J. L.; Siddik, Z. H. Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrinplatinum conjugate. Bioorg. Med. Chem. Lett., 2011, doi:10.1016/ j.bmcl.2011.01.092.
118. rd ed., Wiley, New York, 1972.
119. Kozak, R. W.; Atcher, R. W.; Gansow O. A.; Friedman, A. M.; Hines, J. J. Waldmann, T. A. Bismuth-212-labeled anti-TAC monoclinal antibody: α-particle emitting radionucleotides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA 1986, 83, 474.
120. Brechbiel, M. W.; Pippin, C. G.; McMurry, T. J.; Milenic, D.; Roselli, M.; Colcher, D.; Gansow, O. A. An effective chelating agent for abeling of monoclonal antibody with bismuth-212 for α-particle mediated radiomimmunotherapy. J. Chem. Soc. Chem. Commun., 1991, 1169.
121. Kumar K.; Magerstaedt M.; Gansow, O. A. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids 1,4,7-triazacyclononane-N,N',N"-triacetic acid, 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid, and 1,4,8,11-tetraazacyclotetradecanetetraacetic acid. J. Chem. Soc. Chem. Commun. 1989, 145.
122. Sessler, J. L.; Miller, R. A. Texaphyrins. New Drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol., 2000, 59, 733.
123. Preihs, C.; Arambula, J. F.; Lynch, V. M.; Siddik, Z. H.; Sessler, J. L. Bismuth-and lead-texaphyrin complexes: Towards potential α-core emitters for radiotherapy. Chem. Commun., 2010, 46, 7900.